Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 223

Results For "global"

4814 News Found

Antara AGEasy celebrates one year of advancing senior health solutions
Healthcare | August 21, 2024

Antara AGEasy celebrates one year of advancing senior health solutions

AGEasy has made significant strides in addressing the pressing health concerns of seniors in India


Sequent Scientific receives WHO prequalification approval for Albendazole API
News | August 20, 2024

Sequent Scientific receives WHO prequalification approval for Albendazole API

This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation


Health Minister Nadda inaugurates ‘First Policy Makers’ Forum’ in New Delhi
News | August 20, 2024

Health Minister Nadda inaugurates ‘First Policy Makers’ Forum’ in New Delhi

These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance


Health Minister Nadda reviews Monkeypox situation and preparedness
Policy | August 19, 2024

Health Minister Nadda reviews Monkeypox situation and preparedness

Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management


CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
News | August 19, 2024

CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance

The emergence of new infections in India is a growing concern


Aptar’s nasal unidose system delivers FDA-approved neffy
News | August 19, 2024

Aptar’s nasal unidose system delivers FDA-approved neffy

This marks the first regulatory approval worldwide for nasally-delivered epinephrine


Lupin receives USFDA’s tentative approval for Brimonidine Tartrate Ophthalmic Solution
Drug Approval | August 17, 2024

Lupin receives USFDA’s tentative approval for Brimonidine Tartrate Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.


Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer
Drug Approval | August 17, 2024

Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone